Perspective Therapeutics (CATX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.17, -7.26% vs the prior close of $2.34.
- Volume 1.67M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CATX slides 7.3% to $2.17, a 6-month low. Closed at $2.17, -7.26% vs the prior close of $2.34. Day range $2.15–$2.34, opened at $2.34.
CATX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CATX slides 7.3% to $2.17, a 6-month low
- Closed at $2.17, -7.26% vs the prior close of $2.34. Day range $2.15–$2.34, opened at $2.34.
- Volume was 1.67M shares, 1.0x its 50-day average of 1.72M.
- Price is -24.5% vs its 50-day average ($2.87) and -39.6% vs its 200-day average ($3.59).
- 52-week range $1.96–$6.16; today's close sits at 5% of that range, 64.8% below the 52-week high.
Oct 15, 2026 — CATX jumps 4.5% to $2.34
- Closed at $2.34, +4.46% vs the prior close of $2.24. Day range $2.23–$2.37, opened at $2.27.
- Volume was 1.19M shares, 0.7x its 50-day average of 1.73M.
- Price is -19.0% vs its 50-day average ($2.89) and -34.9% vs its 200-day average ($3.60).
- 52-week range $1.96–$6.16; today's close sits at 9% of that range, 62.0% below the 52-week high.
Oct 14, 2026 — CATX dips 1.3% to $2.24, a 6-month low, 4 down days in a row
- Closed at $2.24, -1.32% vs the prior close of $2.27. Day range $2.21–$2.36, opened at $2.36.
- Volume was 1.39M shares, 0.8x its 50-day average of 1.74M.
- Price is -22.8% vs its 50-day average ($2.90) and -37.7% vs its 200-day average ($3.60).
- 52-week range $1.96–$6.16; today's close sits at 7% of that range, 63.6% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — CATX slides 9.9% to $2.27, a 6-month low, 3 down days in a row
- Closed at $2.27, -9.92% vs the prior close of $2.52. Day range $2.25–$2.52, opened at $2.50.
- Volume was 1.31M shares, 0.8x its 50-day average of 1.74M.
- Price is -22.2% vs its 50-day average ($2.92) and -37.0% vs its 200-day average ($3.60).
- 52-week range $1.96–$6.16; today's close sits at 7% of that range, 63.1% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — CATX slides 5.3% to $2.52
- Closed at $2.52, -5.26% vs the prior close of $2.66. Day range $2.51–$2.67, opened at $2.61.
- Volume was 640.40K shares, 0.4x its 50-day average of 1.74M — lighter than usual.
- Price is -14.1% vs its 50-day average ($2.93) and -30.1% vs its 200-day average ($3.60).
- 52-week range $1.96–$6.16; today's close sits at 13% of that range, 59.1% below the 52-week high.
Oct 9, 2026 — CATX dips 1.8% to $2.66
- Closed at $2.66, -1.85% vs the prior close of $2.71. Day range $2.63–$2.76, opened at $2.71.
- Volume was 1.10M shares, 0.6x its 50-day average of 1.73M.
- Price is -9.5% vs its 50-day average ($2.94) and -26.2% vs its 200-day average ($3.60).
- 52-week range $1.96–$6.16; today's close sits at 17% of that range, 56.8% below the 52-week high.
Oct 8, 2026 — CATX jumps 10.2% to $2.71 on 1.9x normal volume
- Closed at $2.71, +10.16% vs the prior close of $2.46. Day range $2.37–$2.73, opened at $2.43.
- Volume was 3.25M shares, 1.9x its 50-day average of 1.68M — unusually heavy trading.
- Price is -8.0% vs its 50-day average ($2.95) and -24.8% vs its 200-day average ($3.61).
- 52-week range $1.96–$6.16; today's close sits at 18% of that range, 56.0% below the 52-week high.
- SEC filings that day: 8-K.
Oct 7, 2026 — CATX jumps 4.2% to $2.46
- Closed at $2.46, +4.24% vs the prior close of $2.36. Day range $2.32–$2.51, opened at $2.37.
- Volume was 1.29M shares, 0.8x its 50-day average of 1.68M.
- Price is -16.6% vs its 50-day average ($2.95) and -31.8% vs its 200-day average ($3.61).
- 52-week range $1.96–$6.16; today's close sits at 12% of that range, 60.1% below the 52-week high.
Oct 6, 2026 — CATX slides 8.2% to $2.36, a 6-month low
- Closed at $2.36, -8.17% vs the prior close of $2.57. Day range $2.30–$2.60, opened at $2.59.
- Volume was 2.70M shares, 1.6x its 50-day average of 1.64M.
- Price is -20.2% vs its 50-day average ($2.96) and -34.6% vs its 200-day average ($3.61).
- 52-week range $1.96–$6.16; today's close sits at 10% of that range, 61.7% below the 52-week high.
Oct 5, 2026 — CATX slides 6.9% to $2.57 on 2.2x normal volume
- Closed at $2.57, -6.88% vs the prior close of $2.76. Day range $2.48–$2.82, opened at $2.75.
- Volume was 3.56M shares, 2.2x its 50-day average of 1.58M — unusually heavy trading.
- Price is -13.4% vs its 50-day average ($2.97) and -28.8% vs its 200-day average ($3.61).
- 52-week range $1.96–$6.16; today's close sits at 15% of that range, 58.3% below the 52-week high.
Oct 2, 2026 — CATX rises 1.5% to $2.76
- Closed at $2.76, +1.47% vs the prior close of $2.72. Day range $2.69–$2.82, opened at $2.77.
- Volume was 2.62M shares, 1.7x its 50-day average of 1.54M.
- Price is -7.2% vs its 50-day average ($2.97) and -23.5% vs its 200-day average ($3.61).
- 52-week range $1.96–$6.16; today's close sits at 19% of that range, 55.2% below the 52-week high.
CATX latest news & SEC filings
Every SEC filing by or about CATX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 23, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lantheus Alpha Therapy, Llc sold 167,149 shares at $3.15 (≈$526.52K) on Sep 4, 2026
- Lantheus Alpha Therapy, Llc sold 167,149 shares at $3.15 (≈$526.52K) on Sep 4, 2026
- Lantheus Holdings, Inc. sold 167,149 shares at $3.15 (≈$526.52K) on Sep 4, 2026
- Lantheus Holdings, Inc. sold 167,149 shares at $3.15 (≈$526.52K) on Sep 4, 2026
- Lantheus Alpha Therapy, Llc sold 167,149 shares at $3.15 (≈$526.52K) on Sep 4, 2026
- Lantheus Alpha Therapy, Llc sold 167,149 shares at $3.15 (≈$526.52K) on Sep 4, 2026
- …plus 10 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lantheus Holdings, Inc. sold 42,129 shares at $3.11 (≈$131.02K) on Sep 2, 2026
- Lantheus Holdings, Inc. sold 42,129 shares at $3.11 (≈$131.02K) on Sep 2, 2026
- Lantheus Alpha Therapy, Llc sold 42,129 shares at $3.11 (≈$131.02K) on Sep 2, 2026
- Lantheus Alpha Therapy, Llc sold 42,129 shares at $3.11 (≈$131.02K) on Sep 2, 2026
- Lantheus Holdings, Inc. sold 42,129 shares at $3.11 (≈$131.02K) on Sep 2, 2026
- Lantheus Holdings, Inc. sold 42,129 shares at $3.11 (≈$131.02K) on Sep 2, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lantheus Alpha Therapy, Llc sold 35,769 shares at $3.12 (≈$111.60K) on Sep 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 4, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$26.79M (prior year -$21.48M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.22 (prior year -$0.29) (loss narrowed vs Jun 30, 2025)
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 8.01 — Reported other events the company considers important.
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade CATX
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, May 4, 2026, Mar 16, 2026. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.65% (largest 11.5%). That is a volatile stock.
- Liquidity: about 2.04M shares (≈$4.44M) trade per day on average.
- 52-week position: $2.17 vs a range of $1.96–$6.16 (5% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Alpha Therapy, Llc Lantheus sold 167,149 shares on Sep 4, 2026.
- Latest filings: 8-K Oct 8, 2026; 8-K Oct 1, 2026; 8-K Sep 14, 2026.
- Share count: 114.15M shares outstanding (Aug 5, 2026), +53.7% vs a year earlier — notable dilution.
- Listing: NYSE · industry: Pharmaceutical Preparations.
CATX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.34 | 2.34 | 2.15 | 2.17 | 1.67M |
| Oct 15, 2026 | 2.27 | 2.37 | 2.23 | 2.34 | 1.19M |
| Oct 14, 2026 | 2.36 | 2.36 | 2.21 | 2.24 | 1.39M |
| Oct 13, 2026 | 2.50 | 2.52 | 2.25 | 2.27 | 1.31M |
| Oct 12, 2026 | 2.61 | 2.67 | 2.51 | 2.52 | 640.40K |
| Oct 9, 2026 | 2.71 | 2.76 | 2.63 | 2.66 | 1.10M |
| Oct 8, 2026 | 2.43 | 2.73 | 2.37 | 2.71 | 3.25M |
| Oct 7, 2026 | 2.37 | 2.51 | 2.32 | 2.46 | 1.29M |
| Oct 6, 2026 | 2.59 | 2.60 | 2.30 | 2.36 | 2.70M |
| Oct 5, 2026 | 2.75 | 2.82 | 2.48 | 2.57 | 3.56M |
| Oct 2, 2026 | 2.77 | 2.82 | 2.69 | 2.76 | 2.62M |
| Oct 1, 2026 | 2.71 | 2.78 | 2.66 | 2.72 | 1.54M |
| Sep 30, 2026 | 2.64 | 2.78 | 2.55 | 2.75 | 1.67M |
| Sep 29, 2026 | 2.52 | 2.62 | 2.49 | 2.62 | 1.54M |
| Sep 28, 2026 | 2.50 | 2.58 | 2.46 | 2.50 | 1.50M |
| Sep 25, 2026 | 2.50 | 2.53 | 2.45 | 2.52 | 1.80M |
| Sep 24, 2026 | 2.58 | 2.59 | 2.44 | 2.50 | 1.70M |
| Sep 23, 2026 | 2.89 | 2.92 | 2.50 | 2.62 | 3.15M |
| Sep 22, 2026 | 3.00 | 3.02 | 2.81 | 2.96 | 5.15M |
| Sep 21, 2026 | 2.94 | 3.03 | 2.90 | 2.97 | 2.11M |
About Perspective Therapeutics
Perspective Therapeutics (CATX) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SEATTLE, WA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 728387.
CATX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Heidi Henson | Director | Mar 4, 2026 |
| Maria E Martinez | Director | Mar 4, 2026 |
| Frank Morich | Director | Mar 4, 2026 |
| Johan M. Spoor | Chief Executive Officer | Mar 4, 2026 |
| Robert F Iii Williamson | Director | Mar 4, 2026 |
| Lori A Woods | Director | Mar 4, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jonathan Robert Hunt | Chief Accounting Officer | Mar 4, 2026 |
| Markus Puhlmann | Chief Medical Officer | Mar 4, 2026 |
| Johan M. Spoor | Chief Executive Officer | Mar 4, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 4, 2026 | Alpha Therapy, Llc Lantheus | Sale | 167,149 | $3.15 |
| Sep 4, 2026 | Alpha Therapy, Llc Lantheus | Sale | 167,149 | $3.15 |
| Sep 4, 2026 | Holdings, Inc. Lantheus | Sale | 167,149 | $3.15 |
| Sep 4, 2026 | Holdings, Inc. Lantheus | Sale | 167,149 | $3.15 |
| Sep 4, 2026 | Alpha Therapy, Llc Lantheus | Sale | 167,149 | $3.15 |
| Sep 4, 2026 | Alpha Therapy, Llc Lantheus | Sale | 167,149 | $3.15 |
| Sep 4, 2026 | Holdings, Inc. Lantheus | Sale | 167,149 | $3.15 |
| Sep 4, 2026 | Holdings, Inc. Lantheus | Sale | 167,149 | $3.15 |
| Sep 3, 2026 | Alpha Therapy, Llc Lantheus | Sale | 80,783 | $3.11 |
| Sep 3, 2026 | Alpha Therapy, Llc Lantheus | Sale | 80,783 | $3.11 |
| Sep 3, 2026 | Holdings, Inc. Lantheus | Sale | 80,783 | $3.11 |
| Sep 3, 2026 | Holdings, Inc. Lantheus | Sale | 80,783 | $3.11 |
| Sep 3, 2026 | Alpha Therapy, Llc Lantheus | Sale | 80,783 | $3.11 |
| Sep 3, 2026 | Alpha Therapy, Llc Lantheus | Sale | 80,783 | $3.11 |
| Sep 3, 2026 | Holdings, Inc. Lantheus | Sale | 80,783 | $3.11 |
CATX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-103.12M | -1.40 | $-82.48M |
| Dec 31, 2024 | — | $-79.28M | -1.23 | $-18.29M |
| Dec 31, 2023 | — | $-46.51M | -1.74 | $-36.91M |
| Dec 31, 2022 | — | $-10.76M | — | $-10.40M |
| Jun 30, 2022 | — | $-7.27M | — | $-7.71M |
Latest balance sheet: total assets $392.02M, total liabilities $68.16M, cash $48.49M (as of Jun 30, 2026).
CATX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $3.00 |
| May 11, 2026 | 8-K Item 2.02 (results) | $3.88 |
| May 4, 2026 | 8-K Item 2.02 (results) | $3.98 |
| Mar 16, 2026 | 8-K Item 2.02 (results) | $5.22 |
| Feb 2, 2026 | 8-K Item 2.02 (results) | $5.06 |
| Jan 9, 2026 | 8-K Item 2.02 (results) | $2.84 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $2.22 |
| Oct 20, 2025 | 8-K Item 2.02 (results) | $3.19 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $3.81 |
| May 12, 2025 | 8-K Item 2.02 (results) | $2.51 |
| Mar 26, 2025 | 8-K Item 2.02 (results) | $2.27 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $3.40 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CATX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.